Results 121 to 130 of about 41,383 (293)

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience

British Journal of Clinical Pharmacology, EarlyView.
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort, Marella C. E. van Ruissen, Lisanne C. A. Smidt, Naomi B. Klarenbeek, Philip H. K. Kremer, Manon A. A. Jansen, Jacobus Burggraaf, Joop M. A. van Gerven, Matthijs Moerland   +8 more
wiley   +1 more source

Pharmacokinetics, safety, tolerability and fluorescence imaging of nizaracianine triflutate administered in three divided doses to healthy volunteers

British Journal of Clinical Pharmacology, EarlyView.
Aim Fluorescence‐guided surgery enhances intraoperative visualization of anatomical structures. Nizaracianine is a near‐infrared fluorescent agent that is exclusively renally cleared in animal models. It enables real‐time ureteral imaging and identification, potentially reduces risk of injury and facilitates assessment before surgical closure.
Lisanne K. A. Neijenhuis, Cedric M. W. Pesch, John V. Frangioni, Alexander L. Vahrmeijer, Jacobus Burggraaf, Naomi B. Klarenbeek   +5 more
wiley   +1 more source

Factor V Leiden and Thrombophilia

New England Journal of Medicine, 1995
P, Hopmeier, W, Krugluger
openaire   +4 more sources

FV Leiden, Prothrombin II, and MTHFR C677T Mutations in Children and Young Adults with Thromboembolic Diseases

Medical Journal of Babylon
Background: The main markers for estimation of the tendency for thromboembolic disorders are Factor V Leiden, Prothrombin gene (G20210A), and MTHFR (C677T) polymorphism.
Sura O. AL-Dewachi, Wasem Alkafaf, Farah Mudhafar Fattah, Salman Haza, Muna A. Kashmoola   +4 more
doaj   +1 more source

Inflammation‐driven variability in drug metabolism: Insights from voriconazole treatment of HSCT recipients

British Journal of Clinical Pharmacology, EarlyView.
Aims Voriconazole is commonly used to prevent fungal infections after haematopoietic stem cell transplantation (HSCT). Although its metabolism is influenced by CYP2C19 genetics and inflammation, their combined effect is rarely considered in clinical practice, and integrated analyses remain limited.
Sylvia D. Klomp, Martijn L. Manson, Henk‐Jan Guchelaar, Stefan Böhringer, Esther H. M. van Egmond, Peter A. von dem Borne, Jesse J. Swen   +6 more
wiley   +1 more source

Pharmacokinetics and pharmacodynamics of intravenous and oral (S)‐ketamine: Investigating metabolite contribution to subjective effects

British Journal of Clinical Pharmacology, EarlyView.
Aims Oral administration of (S)‐ketamine for treatment‐resistant depression (TRD), as alternative to the registered intranasal or off‐label intravenous administrations, has high potential. However, it is characterized by an extensive first‐pass metabolism, resulting in low (S)‐ketamine exposure and high levels of active metabolites, including (S ...
Marije E. Otto, Gabriël E. Jacobs, Joost C. van Mechelen, Laura G. J. M. Borghans, Johan G. C. van Hasselt, Linda B. S. Aulin   +5 more
wiley   +1 more source

The decline of 6‐thioguanine nucleotides is not linked to impaired efficacy or safety of thiopurines in pregnant women with inflammatory bowel disease

British Journal of Clinical Pharmacology, EarlyView.
Background Thiopurines are used to maintain remission in inflammatory bowel disease (IBD). These drugs are metabolized into 6‐thioguanine nucleotides (6‐TGN), associated with efficacy, and 6‐methylmercaptopurine ribonucleotides (6‐MMPR), associated with adverse drug reactions. Pregnancy has been linked to a shift in thiopurine metabolism, characterized
Dianne G. Bouwknegt, Paola Mian, Femke Groen, Denise van den Berg‐Zuiddam, Andrea E. van der Meulen, Femke Crouwel, Nanne K. de Boer, Debbie S. Deben, Dennis R. Wong, Luc J. J. Derijks, Gerard Dijkstra, Arno R. Bourgonje, C. Janneke van der Woude, Marijn C. Visschedijk   +13 more
wiley   +1 more source

Digital diagnostics, biomarkers and therapeutics in an evolving healthcare system: From promise to practice

British Journal of Clinical Pharmacology, EarlyView.
Abstract Health care is shifting towards a digital‐guided system, integrating digital diagnostics, biomarkers and therapeutics in many care pathways. However, despite rapid technological advancement and preliminary adoption accelerated by the COVID‐19 pandemic, a significant implementation gap persists. This narrative review explores the causes of this
Mees H. P. Stoop, Gertjan J. A. Driessen, Adam F. Cohen, Matthijs D. Kruizinga   +3 more
wiley   +1 more source

Factor V Leiden (fvq 506) Is Common In A Brazilian Population

, 2015
Resistance to activated protein C (APC) is the most common risk factor in venous thrombosis. A missense mutation in the factor V gene (factor V Leiden) is the molecular basis for this phenotype.
Costa F.F., Reitsma P.H., Annichino-Bizzacchi M., Arruda V.R.   +3 more
core   +1 more source

Lack of improvement after short‐term topical antistaphylococcal endolysin SA.100 therapy in patients with mild‐to‐moderate atopic dermatitis: Results from a randomized, vehicle‐controlled trial

British Journal of Clinical Pharmacology, EarlyView.
Abstract Atopic dermatitis (AD) is a chronic immune‐mediated inflammatory skin disease. An overgrowth of Staphylococcus aureus (S. aureus) and decreased microbial diversity is apparent in 70%–90% of AD patients. SA.100 is a recombinant endolysin targeting S. aureus that might be a novel treatment for patients with mild‐to‐moderate AD.
Laura W. J. van der Meulen, Menthe E. Bergmans, Salma Assil, Ismahaan Abdisalaam, Rianne Rijneveld, Erica S. Klaassen, Alexa J. Tibboel, Thorsten Brach, Bjorn L. Herpers, Johan Frieling, Benthe Freyee, Karin Platenkamp, Mariette E. van Poelgeest, Robert Rissmann, Martijn B. A. van Doorn, Tessa Niemeyer – van der Kolk   +15 more
wiley   +1 more source